AbbVie drug Decnupaz received FDA approval for treating blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This antibody drug conjugate came from AbbVie’s 2023 ImmunoGen acquisition.
The post AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer appeared first on MedCity News.
